A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Completed · Phase 3 · Has a placebo group

Conditions studied: Glabellar Lines

In brief

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study was to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in participants with moderate to severe GL. This was a 12-week study in which eligible subjects were enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants were randomly assigned to receive AGN-151586 or placebo. There was 1 in a 4 chance that participants would receive placebo. Around 600 adult participants with moderate to severe GL were to be enrolled in the study in approximately 38 sites across the world. Participants received either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may have received an open-label treatment of AGN-151586 during the study. Participants attended regular visits during the study at a study site. The effect of the treatment was checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

Key facts

Study ID

NCT05248867

Run by

AbbVie

People needed

638

Starts

2022-03-16

Expected to finish

2023-03-17

Last updated by the study team

2024-05-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).
• Participant must have moderate or severe Glabellar Lines at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline Day 1 visit.

You may not qualify if…

• Uncontrolled systemic disease.
• Presence or history of any medical condition that may place the participant at increased risk following exposure to AGN-151586 or interfere with the study evaluation, including:
• Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
• History of facial nerve palsy
• Infection or dermatological condition at the treatment injection sites
• Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart
• Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined by the investigator
• History of known immunization to any botulinum neurotoxin serotype.
• Participants who have reported use of any botulinum neurotoxin of any serotype (including any investigational botulinum neurotoxin product) for aesthetic treatment within the last 6 months prior to Baseline (Day 1 of treatment) and for therapeutic treatment within the last 12 months prior to study drug administration.
• Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.
• Anticipated need for surgery or overnight hospitalization during the study.
• History of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).
• History of periorbital, mid-facial, or upper-facial treatment with semi-permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
• Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• Female participant who is pregnant or breastfeeding, and is considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug or until the end of study, whichever is longer.
• Participant who has been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.
• Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study drug).

Where it is running

• Total Skin and Beauty Derm Ctr /ID# 232378 — Birmingham, Alabama, United States
• Clinical Testing of Beverly Hills /ID# 233195 — Encino, California, United States
• Westside Aesthetics /ID# 232443 — Los Angeles, California, United States
• The Research Center at The Maas Clinic /ID# 241262 — San Francisco, California, United States
• Center for Dermatology and Dermatologic Surgery /ID# 232315 — Washington D.C., District of Columbia, United States
• Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439 — Boca Raton, Florida, United States
• Dermatology Clinic & Cosmetic Center /ID# 244295 — Baton Rouge, Louisiana, United States
• Delricht Research /ID# 241253 — New Orleans, Louisiana, United States
• Skincare Physicians /ID# 233938 — Chestnut Hill, Massachusetts, United States
• BOYD Beauty Birmingham /ID# 232383 — Birmingham, Michigan, United States
• Skin Search of Rochester Inc. /ID# 232549 — Rochester, New York, United States
• Aesthetic Solutions /ID# 232389 — Chapel Hill, North Carolina, United States
• Aventiv Research Dublin /ID# 233936 — Dublin, Ohio, United States
• KGL Skin Study Center, LLC /ID# 233549 — Newtown Square, Pennsylvania, United States
• Nashville Center for Laser and Facial Surgery /ID# 242535 — Nashville, Tennessee, United States
• Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232410 — Austin, Texas, United States
• Dallas Plastic Surgery Institute /ID# 232328 — Dallas, Texas, United States
• Austin Institute for Clinical Research at SBA Dermatology /ID# 232316 — Houston, Texas, United States
• Beacon Dermatology Inc /ID# 233227 — Calgary, Alberta, Canada
• Alberta DermaSurgery Centre /ID# 241172 — Edmonton, Alberta, Canada
• Dr. Wei Jing Loo Medicine Prof /ID# 241863 — London, Ontario, Canada
• Erevna Innovations Inc. /ID# 239592 — Westmount, Quebec, Canada
• Studienzentrum Theatiner46 /ID# 241185 — Munich, Bavaria, Germany
• Rosenpark Research /ID# 232391 — Darmstadt, Hesse, Germany
• Privatpraxis Dr. Hilton & Partner /ID# 232392 — Düsseldorf, North Rhine-Westphalia, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.